Lercanidipine

ApprovedSmall molecule

LLee's Pharmaceutical Limited

Lercanidipine is one of 96 small molecule programs targeting Renal artery stenosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Artery StenosisActive, not recruiting

Essential HypertensionActive, not recruiting

Angina PectorisActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Renal Artery StenosisApproved

Active, not recruiting

Essential HypertensionPhase 2

Active, not recruiting

Angina PectorisPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Lercanidipine

LLee's Pharmaceutical Limited

Approved

1 2

Aranesp

Amgen

Preclinical

40 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Uloric

Takeda

Preclinical

3 5

Sovaldi

Gilead

Preclinical

1 6

Glucotrol

Pfizer

Preclinical

1 7

Vemlidy

Gilead

Preclinical

1 8

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Obesity, Morbid

NCT03497156

Q4 2039

N/ARecruiting

Chronic Kidney Disease

NCT07020104

Clinical

Trials by Indication[1]

Essential Hypertension2 trials

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Completed·RRECORDATI GROUP·Phase 2·NCT01093807·1,039 enrolled

Intensive Vasodilator Therapy in Patients With Essential Hypertension

Completed·—·Phase 4·NCT01180413·48 enrolled

Angina Pectoris1 trial

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Terminated·UUniversity of Aarhus·N/A·NCT00424801·10 enrolled

Chronic Kidney Disease1 trial

The Role of Skin Sodium Accumulation in Chronic Kidney Disease

Recruiting·—·N/A·NCT07020104·60 enrolled

Renal artery stenosis1 trial

Zainidip in Renal Artery Stenosis

Completed·LLee's Pharmaceutical Limited·Phase 4·NCT02594410·149 enrolled

Efficacy and Safety1 trial

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Completed·LLG Life Sciences·Phase 3·NCT01928628·449 enrolled

3 more indications

Hypertensive1 trial

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

Unknown status·UUniversità degli Studi dell'Insubria·Phase 4·NCT00564057·30 enrolled

Blood Pressure1 trial

Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients

Completed· UCB logo

UCB·N/A·NCT00160498·180 enrolled

Obesity, Morbid1 trial

Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine

Recruiting·NNorwegian University of Science and Technology··NCT03497156·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Lercanidipine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lercanidipine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lercanidipine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lee's Pharmaceutical Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: LLee's Pharmaceutical Limited

Lercanidipine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2039

Trials by Indication[1]

Essential Hypertension2 trials

Angina Pectoris1 trial

Chronic Kidney Disease1 trial

Renal artery stenosis1 trial

Efficacy and Safety1 trial

Hypertensive1 trial

Blood Pressure1 trial

Obesity, Morbid1 trial

References

Drug Info

Quick Facts

Related News